ACADIA Pharmaceuticals Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; balance-sheet comparisons are to December 31, 2011. ACADIA is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurological and central nervous system disorders. Its lead candidate, pimavanserin, was in Phase III development for Parkinson’s disease psychosis. The company had no product-sales revenue.
Financial results and position
| Metric | Q1 2012 | Q1 2011 / prior balance date |
|---|---|---|
| Revenue, principally collaboration and grant revenue | $0.45 million | $0.435 million |
| Research and development expense | $5.021 million | $4.412 million |
| General and administrative expense | $1.660 million | $1.884 million |
| Total operating expenses | $6.681 million | $6.296 million |
| Operating loss | $6.231 million | $5.861 million |
| Net loss | $6.218 million; $0.12 per share | $5.833 million; $0.12 per share |
| Cash used in operating activities | $5.230 million | $5.107 million |
| Cash, cash equivalents and investment securities | $25.9 million | $31.0 million |
| Total assets / total liabilities | $26.519 million / $8.934 million | $32.114 million / $8.752 million |
Net loss margin was not meaningful given the company’s minimal collaboration revenue and lack of product sales; the filing does not report a gross margin. At March 31, cash and cash equivalents were $5.558 million and available-for-sale securities were $20.366 million. Current liabilities were $6.433 million, including $22,000 of current debt; the balance sheet lists no separate non-current debt balance. Deferred revenue totaled approximately $3.184 million. Management said existing cash, investments and anticipated collaboration payments were expected to fund operations at least into the second quarter of 2013, while also stating that significant additional financing would be needed in the future.
Changes from the comparable period and prior year-end
- Revenue increased $15,000 year over year. Allergan revenue was unchanged at $264,000; revenue from other parties, including Meiji Seika Pharma and research grants, rose to $186,000 from $171,000.
- R&D expense increased $609,000, primarily because external service costs rose $1.2 million, largely reflecting higher clinical costs in the pimavanserin Phase III program. Lower internal R&D costs partly offset the increase.
- G&A expense fell $224,000, mainly due to reduced personnel and other internal costs. The net loss widened $385,000.
- Cash, cash equivalents and investments fell $5.1 million from year-end. Operating cash use was $5.2 million; investing activities provided $3.9 million as investment maturities exceeded purchases. Financing provided only $22,000, compared with $13.8 million in Q1 2011, when the company completed a private equity financing.
- Accrued expenses rose to $4.693 million from $3.504 million, primarily due to increased accrued clinical and research services. Stockholders’ equity declined to $17.585 million from $23.362 million.
Outlook, developments and principal risks
- ACADIA expected continued operating losses for at least several years and substantial external R&D spending. It could not estimate development costs or completion dates with certainty, given clinical-development risks and program uncertainty.
- In March 2012, ACADIA established an at-the-market agreement allowing it to sell up to $20 million of common stock over three years. No shares had been sold under the agreement by the filing date; use was optional, and sales would incur a 3% commission.
- The Allergan ophthalmology research term was extended through March 2013. A $322,000 Michael J. Fox Foundation supplemental grant for Nurr1-RXR agonist research was awarded in March, with activities beginning in Q2 2012.
- Key risks include the need to raise additional capital, uncertain clinical outcomes, and reliance on collaborators for funding and development of selected programs. ACADIA noted a prior unsuccessful Phase III pimavanserin trial and identified an unfavorable outcome in its ongoing Phase III study as a major risk. It also disclosed that Allergan was seeking a partner for the chronic-pain program, with a risk that development could be reduced or stopped.
- Potential financing sources include collaborations, equity or debt offerings, grants, and licensing. If adequate funding is unavailable, ACADIA said it may delay, reduce, or eliminate programs or relinquish product rights. The filing also identifies clinical-trial, regulatory, manufacturing, intellectual-property, collaboration, and market-acceptance risks.
- Contract research and external-service agreements represented up to approximately $4.3 million of future services, generally stoppable on short notice without liability for the full amount. Separate operating-lease and debt obligations totaled $590,000, all due within one year. Potential Ipsen milestone payments of up to $10.5 million were contingent and excluded from that obligations table.
- Management reported effective disclosure controls as of March 31, 2012 and no material change in internal control over financial reporting during the quarter. A 10% interest-rate change was not expected to materially affect the investment portfolio’s fair value.
Important facts for investors to verify
- Current status, results, timing, and funding requirements of the pimavanserin Phase III program, including the implications of the earlier failed trial.
- Whether the company’s stated cash runway into Q2 2013 remains achievable, considering clinical spending, collaboration payments, and access to new capital.
- Progress of Allergan’s search for a chronic-pain partner and the renewal or continuation of collaboration research after March 2013.
- Potential dilution if ACADIA uses the $20 million ATM facility or other equity financing, and the status of the registered shares from the 2011 financing.
- Actual timing and potential costs of clinical commitments, collaboration obligations, and contingent Ipsen milestones.